Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 4Neoplasm Metastasis 4Urogenital Neoplasms 1Solitary Fibrous Tumors 1Solid Tumors Harboring NTRK Fusion 1Small Cell Lung Carcinoma 1Sarcoma 1Respiratory Syncytial Virus Infections 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Neuroblastoma 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Lung Neoplasms 1Kidney Neoplasms 1Granuloma, Plasma Cell 1Glioma 1Glioblastoma 1Genital Neoplasms, Male 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

remdesivir 1Suspensions 1Specimen Handling 1Ribavirin 1Injections 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Respiratory Syncytial Virus Infections × Suspensions × Clear all
NCT06597916 2024-11-27

RSV Vaccination in Immunocompromised Patients.

Medical University of Vienna

Phase 2 Recruiting
200 enrolled

Respiratory Syncytial Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡